Roughly 173 drug programs that trace their origin to AI-driven discovery platforms are currently sitting in clinical trials. Not one of them has crossed the finish line to full FDA approval. That single fact sits awkwardly next to years of press releases promising that AI would compress a decade of drug discovery into months. It's worth asking what's actually happening in the space between those two numbers — because the answer says more about how drug development works than it does about whether the AI is any good.
This isn't a story about AI failing at drug discovery. It's a story about what "AI discovered this drug" actually means, how long clinical trials take regardless of how a molecule was found, and where the real evidence of impact is starting to show up — which is not, yet, in an approval letter.
What "AI-discovered" actually means
The phrase gets used loosely, and that looseness is doing a lot of work in the hype cycle. A drug labeled "AI-discovered" can mean several very different things:
- De novo molecular generation — a generative model proposes novel chemical structures with desired properties, and a candidate emerges that a chemist did not hand-draw first.
- Target identification — AI models mine genomic, proteomic, or literature data to flag a biological target (a protein or pathway) as promising, and a conventional discovery process takes it from there.
- Hit-to-lead optimization — AI narrows a massive virtual chemical library down to a shortlist of candidates for wet-lab testing, accelerating a step that used to take human medicinal chemists months.
- Repurposing and combination prediction — AI models predict that an existing approved drug (or combination of drugs) will work against a new disease, sidestepping de novo chemistry entirely.
Companies like Insilico Medicine, Recursion Pharmaceuticals, Exscientia (now part of Recursion), Isomorphic Labs, and BenevolentAI each anchor their public narrative in different parts of this list. Insilico is probably the closest to the popular image — an AI system (its Chemistry42 and PandaOmics platforms) proposed a novel target and a novel molecule for idiopathic pulmonary fibrosis, and that candidate, rentosertib, reached clinical trials. Recursion leans harder on phenotypic screening — using AI to interpret millions of cellular images and infer which molecules do useful things to diseased cells, without necessarily starting from a known target.
The point is that "AI-discovered drug" is a spectrum, not a category. A drug where AI shaved a few months off target selection is being counted in the same public conversation as a drug whose entire molecular structure was generated by a model. That conflation is part of why the headline numbers — hundreds of AI-associated programs — can coexist with zero full approvals without anyone being obviously wrong. The claims being made are just fuzzier than they sound.
How the pipeline actually works, and why speed at one stage doesn't mean speed overall
Drug development has four broad phases after a candidate is chosen: preclinical testing (in vitro and animal studies), then Phase 1 (safety, small healthy or patient cohorts), Phase 2 (efficacy signal, larger patient group), and Phase 3 (large-scale confirmatory efficacy, often the longest and most expensive phase). Only after clearing all three clinical phases does a sponsor file for approval, and regulators then take months to over a year to review the submission.
Where AI has demonstrably compressed timelines is almost entirely in the earliest, most computational stages:
| Stage | Traditional timeline | AI-assisted timeline (claimed) | What AI is actually doing |
|---|---|---|---|
| Target identification | 1–3 years | Weeks to months | Mining omics/literature data for candidate targets |
| Hit discovery / lead optimization | 2–4 years | Months | Screening virtual libraries, generating novel structures |
| Preclinical candidate nomination | 1–2 years | Similar, sometimes faster | Predicting toxicity/ADME properties in silico |
| Phase 1 (safety) | 1–2 years | Unchanged | Governed by regulatory and biological timelines |
| Phase 2 (efficacy signal) | 2–3 years | Unchanged | Governed by patient recruitment, disease biology |
| Phase 3 (confirmatory) | 2–4 years | Unchanged | Governed by statistical power, endpoints, follow-up |
| Regulatory review | 1–1.5 years | Unchanged | FDA/EMA process, not compressible by discovery method |
The compression is real but structurally limited to roughly the first 3-5 years of what is typically a 10-12 year process. Once a molecule enters human trials, it is subject to the same biology, the same regulatory scrutiny, and the same patient recruitment bottlenecks as any other candidate — AI-originated or not. A model can find a promising molecule in months; it cannot make a Phase 3 cardiovascular outcomes trial finish faster, because that trial's duration is set by how long it takes enough patients to have enough cardiac events to reach statistical significance.
This is the mechanical reason the "zero approvals" number is not itself damning. The earliest AI-native platforms (Exscientia, BenevolentAI, Insilico) only started nominating clinical candidates in volume around 2020-2022. Given a typical clinical-to-approval timeline of 8-12 years even for well-behaved candidates, an approval wave — if it's coming — would be expected to land in the back half of this decade at the earliest, not before it.
Why now: 173 programs, zero approvals, and what that gap means
The ~173 figure matters because it establishes scale: this is no longer a handful of speculative bets from a few well-funded startups. It represents a meaningful slice of the industry's early-stage pipeline. Large pharmaceutical companies have folded AI-discovery partnerships into standard R&D practice rather than treating them as experimental side projects — Isomorphic Labs (spun out of Alphabet's DeepMind) has signed structured discovery deals with major pharma partners, and most top-20 pharma companies now run internal AI discovery units alongside external platform partnerships.
But the zero-approvals figure is the sobering counterweight, and it deserves to be stated plainly rather than explained away. It means that, as of today, no regulator has yet confirmed through the full clinical gauntlet that an AI-native discovery process reliably produces drugs that are safer or more effective than those found through conventional means. Every claim about AI's superiority in drug discovery is currently a claim about speed and cost at the discovery stage — not about the clinical outcomes of the resulting molecules, because the industry doesn't have enough completed Phase 3 data yet to know.
Some of the earliest and most closely watched candidates are also the best evidence of what a nuanced picture looks like:
- Insilico Medicine's rentosertib (INS018_055) for idiopathic pulmonary fibrosis is widely cited as the field's flagship case — a novel target and novel molecule both nominated by AI, in trials since 2021 and reporting encouraging Phase 2a safety and biomarker data.
- Exscientia/Recursion's oncology candidates have had a mixed record, including at least one high-profile program discontinuation, a useful reminder that AI-originated molecules fail in trials for the same reasons any molecule fails: toxicity, lack of efficacy, or an underlying disease hypothesis that doesn't hold up in humans.
- BenevolentAI's early repurposing work (including its widely publicized baricitinib prediction for COVID-19, later borne out) showed AI's target/indication-matching strength, even though that specific case involved an already-approved drug rather than a novel molecule going through full clinical development.
The honest synthesis: AI is unambiguously changing how candidates get selected and how fast they reach the clinic. It has not yet been shown to change the probability that a candidate survives the clinic — because we don't yet have a large enough completed cohort to measure that probability with any confidence.
Practical implications for pharma, biotech, and investors
For organizations deciding how much to bet on AI-native discovery, the current data supports a specific and fairly narrow set of conclusions rather than a blanket endorsement or dismissal.
For pharma and biotech R&D leaders:
- Treat AI discovery platforms as a tool for improving the quality and speed of your candidate funnel, not as a guarantee of downstream clinical success. The evidence supports faster, cheaper hit-to-lead work; it does not yet support lower attrition rates in the clinic.
- Budget for the same clinical trial costs and timelines regardless of discovery method. Any internal projection that assumes AI-discovered candidates will reach approval meaningfully faster than industry-average timelines is not supported by data yet — it's a hypothesis.
- Evaluate AI discovery vendors on the rigor of their validation data (retrospective accuracy on known targets, prospective hit rates) rather than on marketing language about "AI-designed" molecules. Ask specifically which stage of the funnel the AI touched.
For investors and business development teams:
- Attrition math still applies. Industry-wide, roughly 90% of drug candidates that enter Phase 1 fail to reach approval; there is no published, statistically robust evidence yet that AI-originated candidates beat that baseline, though several companies claim internal data suggesting improved hit rates at the preclinical stage.
- Licensing and partnership deals structured around AI platforms (the Isomorphic Labs model, for instance) are effectively bets on target-selection quality, not de-risked clinical assets. Price them accordingly.
- The 2026-2028 window is when the first meaningful wave of AI-native Phase 3 readouts is expected. That is the period to watch for real signal, not press releases about new candidates entering trials.
For builders and technical teams working adjacent to this space, the more immediate opportunity often isn't the generative chemistry itself but the infrastructure around it: cleaning and structuring the multi-modal biological data these models train on, building the MLOps and validation pipelines that make model predictions auditable to a regulator, and integrating AI tooling into the messy reality of existing lab and clinical-data systems. That infrastructure work has clear, near-term ROI regardless of how the novel-molecule story eventually resolves.
Real limitations and open questions
A few limitations are structural, not just a matter of the technology maturing further.
Data quality and bias. Generative and predictive models are trained on existing bioactivity, structural, and omics datasets, which carry the biases of decades of prior drug discovery — overrepresenting certain target classes and chemical scaffolds that were historically easy to study, and underrepresenting biology that's harder to assay. A model trained on this data will tend to propose more of what's already been explored, which cuts against the "AI finds things humans would never find" narrative in some cases.
Validation is retrospective by default. Most published accuracy claims for AI discovery models are backtested against known outcomes — can the model "rediscover" an approved drug or a known toxic liability? That's a necessary but not sufficient test. Prospective validation, where the model's prediction precedes and is confirmed by a real, blinded clinical result, is much rarer and takes years to accumulate.
Biology, not chemistry, is usually the bottleneck. Many Phase 2 and 3 failures happen because the underlying disease hypothesis was wrong — the target didn't matter as much as preclinical models suggested, or human biology diverged from animal models in ways nobody could have modeled. AI is good at chemistry and target-matching within a known hypothesis space. It does not yet solve the harder problem of validating disease biology itself.
Regulatory frameworks are still catching up. The FDA has issued draft guidance on AI use in drug development, but there's no finalized, AI-specific approval pathway. Every AI-originated candidate currently goes through the identical regulatory process as a conventionally discovered one — which is arguably appropriate (safety and efficacy standards shouldn't change based on how a molecule was found) but means AI gets no regulatory shortcut to offset its earlier-stage speed gains.
Selection effects in reporting. Companies publicize their AI-discovery wins prominently and are far quieter about discontinued programs. The true success rate of AI-originated candidates relative to industry baselines is harder to assess than the marketing suggests, simply because the denominator (quiet failures) is undercounted in public discourse.
What to watch next
The next 24-36 months will produce the first real evidence base, not just pipeline announcements. A few concrete markers to track:
| Signal | Why it matters |
|---|---|
| First Phase 3 readouts from AI-native candidates (2026-2028) | Will show whether AI-originated molecules have comparable or better efficacy/safety rates than industry baselines |
| Any full FDA approval of an AI-discovered novel molecule | The symbolic and practical milestone the field is waiting on |
| Published prospective (not retrospective) validation studies | Needed to assess whether AI predictions hold up before, not after, results are known |
| FDA finalized AI/ML guidance for drug development | Will clarify whether discovery method affects submission requirements |
| Attrition-rate comparisons across large AI-originated cohorts | The real test of whether AI improves candidate quality, not just speed |
| Consolidation or new entrants among AI discovery platforms | Signals whether investor confidence tracks clinical progress or outpaces it |
If the 173 current programs mature at anything close to typical industry attrition rates, expect somewhere in the range of 15-25 to eventually reach approval — a number that would be a genuine milestone for the field, even though it would represent a minority of the total pipeline. That's not a failure of the technology; it's how drug development works for every discovery method that's ever existed. The question worth tracking isn't whether AI produces miracle hit rates — it's whether it produces meaningfully better ones than the conventional process it's being compared against, and whether it does so cheaply enough to matter.
FAQ
Has any AI-discovered drug been approved by the FDA?
No AI-originated drug has yet received full FDA approval. Several candidates, including Insilico Medicine's rentosertib, have advanced through Phase 2 trials and are considered the field's furthest-along programs, but full approval — which requires completing Phase 3 and regulatory review — has not yet happened for any of them.
How many AI-discovered drugs are currently in clinical trials?
Estimates put the number at roughly 173 AI-originated drug programs currently in some stage of clinical development, spanning companies like Insilico Medicine, Recursion Pharmaceuticals, Exscientia, and BenevolentAI, among others.
Why hasn't AI sped up the entire drug development timeline?
AI has mainly accelerated the early, computational stages of discovery — target identification and molecule design — which historically take 3-5 years. Clinical trials themselves are governed by biological response times, patient recruitment, and regulatory review, none of which a discovery algorithm can compress.
Is AI drug discovery actually better than traditional methods, or just faster?
The current evidence supports faster and cheaper early-stage discovery. Whether AI-originated candidates have better clinical success rates than conventionally discovered ones is not yet established, because too few AI-native candidates have completed the full clinical pipeline to generate statistically meaningful attrition data.
What's the difference between an AI-assisted drug and an AI-discovered drug?
"AI-assisted" typically means AI sped up one step of a largely conventional process, such as virtual screening or toxicity prediction. "AI-discovered" is often used more loosely, but the strongest form of the claim applies to cases where a generative model proposed a genuinely novel molecular structure and, sometimes, a novel biological target.
Which companies are leading in AI drug discovery?
Insilico Medicine, Recursion Pharmaceuticals, Isomorphic Labs, and BenevolentAI are among the most visible AI-native discovery companies, alongside internal AI units at large pharmaceutical companies that partner with or license technology from these platforms.
When might we see the first approved AI-discovered drug?
Given that the earliest AI-native clinical candidates entered trials around 2020-2021 and typical clinical-to-approval timelines run 8-12 years, the first approvals are plausible in the 2027-2030 window, though this depends entirely on how individual Phase 2 and Phase 3 trials read out.
Teams evaluating where AI genuinely changes drug discovery outcomes versus where it just changes the marketing copy can get a clearer, hands-on assessment from Woyce Technologies.